Year |
Citation |
Score |
2017 |
Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis. Molecular Cancer Therapeutics. PMID 28468780 DOI: 10.1158/1535-7163.Mct-16-0821 |
0.41 |
|
2012 |
Rodina A, Moulick K, Ahn J, Zong H, Cerchietti L, DaGama EG, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu L, Zhao X, Zatorska D, Taldone T, Smith-Jones P, et al. Abstract 3029: Biochemical evidence towards the existence of an oncogenic Hsp90 complex Cancer Research. 72: 3029-3029. DOI: 10.1158/1538-7445.Am2012-3029 |
0.678 |
|
2012 |
Gomes-DaGama EM, Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Lopes-Vazquez MEC, Beebe K, Perna F, Katerina C, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, et al. Abstract 1263: Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90 Cancer Research. 72: 1263-1263. DOI: 10.1158/1538-7445.Am2012-1263 |
0.642 |
|
2011 |
Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature Chemical Biology. 7: 818-26. PMID 21946277 DOI: 10.1038/Nchembio.670 |
0.675 |
|
2011 |
Taldone T, Zatorska D, Patel PD, Zong H, Rodina A, Ahn JH, Moulick K, Guzman ML, Chiosis G. Design, synthesis, and evaluation of small molecule Hsp90 probes. Bioorganic & Medicinal Chemistry. 19: 2603-14. PMID 21459002 DOI: 10.1016/J.Bmc.2011.03.013 |
0.637 |
|
2011 |
Ahn JH, Luo W, Kim J, Rodina A, Clement CC, Aguirre J, Sun W, Kang Y, Maharaj R, Moulick K, Zatorska D, Kokoszka M, Brodsky JL, Chiosis G. Design of a flexible cell-based assay for the evaluation of heat shock protein 70 expression modulators. Assay and Drug Development Technologies. 9: 236-46. PMID 21133677 DOI: 10.1089/Adt.2010.0327 |
0.676 |
|
2009 |
Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y, Wu N, de Stanchina E, White J, Gross SS, Ma Y, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America. 106: 8368-73. PMID 19416831 DOI: 10.1073/Pnas.0903392106 |
0.63 |
|
2007 |
Du Y, Moulick K, Rodina A, Aguirre J, Felts S, Dingledine R, Fu H, Chiosis G. High-throughput screening fluorescence polarization assay for tumor-specific Hsp90. Journal of Biomolecular Screening. 12: 915-24. PMID 17942784 DOI: 10.1177/1087057107306067 |
0.646 |
|
2007 |
Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, Litz J, Clement CC, Kang Y, She Y, Wu N, Felts S, Wipf P, Massague J, Jiang X, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nature Chemical Biology. 3: 498-507. PMID 17603540 DOI: 10.1038/Nchembio.2007.10 |
0.644 |
|
2007 |
Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proceedings of the National Academy of Sciences of the United States of America. 104: 9511-6. PMID 17517623 DOI: 10.1073/Pnas.0701055104 |
0.605 |
|
2006 |
Moulick K, Clement CC, Aguirre J, Kim J, Kang Y, Felts S, Chiosis G. Synthesis of a red-shifted fluorescence polarization probe for Hsp90. Bioorganic & Medicinal Chemistry Letters. 16: 4515-8. PMID 16797988 DOI: 10.1016/J.Bmcl.2006.06.025 |
0.521 |
|
2006 |
Chiosis G, Rodina A, Moulick K. Emerging Hsp90 inhibitors: from discovery to clinic. Anti-Cancer Agents in Medicinal Chemistry. 6: 1-8. PMID 16475922 DOI: 10.2174/187152006774755483 |
0.683 |
|
2006 |
Chiosis G, Rodina A, Kim J, Aguirre J, Moulick K, Lopes EC, Wu N, She Y. 419 POSTER Defining Hsp90 as inhibitor of apoptosis in small cell lung cancer European Journal of Cancer Supplements. 4: 128. DOI: 10.1016/S1359-6349(06)70424-4 |
0.61 |
|
Show low-probability matches. |